Furthermore, PI3K/AKT signaling directly regulated glucose transporter 4 and glucose metabolic enzymes [45, 46], therefore, combined PI3K and CD36 inhibitors might restrict the energy supply for tumor growth by synergistically reducing exogenous FAs and glucose resources. This evidence concerns the gene CD36 and neoplasm.